Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis.
Isoniazid is a frontline drug used in the treatment of tuberculosis (TB). Isoniazid is a prodrug, requiring activation in the mycobacterial cell by the catalase/peroxidase activity of the katG gene product. TB kills two million people every year and the situation is getting worse due to the increase in prevalence of HIV/AIDS and emergence of multidrug-resistant strains of TB. Arylamine N-acetyltransferase (NAT) is a drug-metabolizing enzyme (E.C. 2.1.3.5). NAT can acetylate isoniazid, transferring an acetyl group from acetyl coenzyme A onto the terminal nitrogen of the drug, which in its N-acetylated form is therapeutically inactive. The bacterium responsible for TB, Mycobacterium tuberculosis, contains and expresses the gene encoding the NAT protein. Isoniazid binds to the NAT protein from Salmonella typhimurium and we report here the mode of binding of isoniazid in the NAT enzyme from Mycobacterium smegmatis, closely related to the M. tuberculosis and S. typhimurium NAT enzymes. The mode of binding of isoniazid to M. smegmatis NAT has been determined using data collected from two distinct crystal forms. We can say with confidence that the observed mode of binding of isoniazid is not an artifact of the crystallization conditions used. The NAT enzyme is active in mycobacterial cells and we propose that isoniazid binds to the NAT enzyme in these cells. NAT activity in M. tuberculosis is likely therefore to modulate the degree of activation of isoniazid by other enzymes within the mycobacterial cell. The structure of NAT with isoniazid bound will facilitate rational drug design for anti-tubercular therapy.
Sandy
James
J
Department of Pharmacology, Oxford University, Mansfield Road, Oxford, OX1 3QT, United Kingdom. james.sandy@pharm.ox.ac.uk
Holton
Simon
S
Fullam
Elizabeth
E
Sim
Edith
E
Noble
Martin
M
D000995:Antitubercular Agents / Q000378:metabolism*; D001191:Arylamine N-Acetyltransferase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D002374:Catalase / Q000378:metabolism; D020134:Catalytic Domain; D003460:Crystallization; D007538:Isoniazid / Q000378:metabolism*; D007700:Kinetics; D020102:Mycobacterium smegmatis / Q000201:enzymology* / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
D000995:Antitubercular Agents; D002374:Catalase; D009195:Peroxidase; D001191:Arylamine N-Acetyltransferase; D007538:Isoniazid
Microbiology. 2001 Dec;147(Pt 12):3295-302
11739761
Annu Rev Biochem. 1995;64:29-63
7574484
J Biol Chem. 1971 May 25;246(10):3250-8
5103348
J Biol Chem. 2004 Sep 10;279(37):38991-9
15231843
J Am Chem Soc. 2001 Apr 25;123(16):3832-3
11457121
Nature. 1992 Aug 13;358(6387):591-3
1501713
J Exp Med. 2004 May 3;199(9):1191-9
15117974
Biochem J. 2005 Aug 15;390(Pt 1):115-23
15869465
J Mol Biol. 2002 May 10;318(4):1071-83
12054803
Prog Lipid Res. 1998 Jul-Aug;37(2-3):143-79
9829124
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
J Biol Chem. 2004 May 21;279(21):22131-7
15039438
Mol Microbiol. 2000 Nov;38(3):514-25
11069675
Mol Microbiol. 2001 Oct;42(2):309-17
11703656
Bioorg Med Chem Lett. 2003 Aug 4;13(15):2527-30
12852958
J Bacteriol. 1993 Jul;175(13):4255-9
8320241
Bioorg Med Chem. 2003 Apr 3;11(7):1227-34
12628650
Microbes Infect. 2000 May;2(6):659-69
10884617
J Bacteriol. 1999 Feb;181(4):1343-7
9973365
Protein Expr Purif. 2003 Jan;27(1):75-84
12509987
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
15299374
J Biol Chem. 2002 Apr 5;277(14):12175-81
11799105
Protein Expr Purif. 2002 Feb;24(1):138-51
11812235
Science. 1998 Jan 2;279(5347):98-102
9417034
Protein Eng. 1995 Feb;8(2):127-34
7630882
Biochim Biophys Acta. 2003 Mar 17;1620(1-3):8-14
12595067